VivoSeq
Musculoskeletal

Osteoarthritis, Hip

13

Pipeline Programs↗

1

Active Trials↗

10

Companies Involved↗

Osteoarthritis, Hip is an emerging landscape with 13 programs across 10 companies. The most active players are Amgen, Purdue Pharma LP, ANS Pharma. 7 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

40/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 2P

Purdue Pharma LP

1 program

Phase 3A

ANS Pharma

1 program

Phase 3R

Rhodes Pharmaceuticals, L.P.

1 program

ApprovedP

Protega

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

12 of 14 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody214%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 93% of 15 pipeline programs.

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

The Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With Osteoarthritis: A Cross-over, Cluster Randomized Controlled, Non-inferiority Trial Based on National Quality Databases. ProHipQ-OA
Completed·—·Preclinical·NCT05530551·20,000 enrolled
A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
Recruiting·PPoznan University of Medical Sciences·Preclinical·NCT07581470·198 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)